Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3168632 | 1.00 | CA1 (0.42) | CA1CA2CA12CA9EPHX1 | |
| Cyclohexane SCHEMBL10804991 | 1.00 | CA1 (0.42) | CA1CA2CA12CA9EPHX1 | |
| SCHEMBL221594 | 1.00 | — | — | |
| SCHEMBL3416195 | 1.00 | CA1 (0.42) | CA1CA2CA12CA9EPHX1 | |
| SCHEMBL3415460 | 1.00 | CA1 (0.42) | CA1CA2CA12CA9EPHX1 | |
| SCHEMBL3415468 | 1.00 | CA1 (0.42) | CA1CA2CA12CA9EPHX1 | |
| SCHEMBL3413582 | 1.00 | — | — | |
| SCHEMBL8530196 | 1.00 | CA1 (0.42) | CA1CA2CA12CA9EPHX1 | |
| SCHEMBL4473841 | 1.00 | CA1 (0.42) | CA1CA2CA12CA9EPHX1 | |
| SCHEMBL1683865 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096097-B1 | METHOD FOR PRODUCING OXIDATION PRODUCT OF CYCLOALKANE | DAICEL CHEM (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-7834217-B2 | Method for producing oxidation product of cycloalkane | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100081848-A1 | METHOD FOR PRODUCING OXIDATION PRODUCT OF CYCLOALKANE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2096097-A1 | METHOD FOR PRODUCING OXIDATION PRODUCT OF CYCLOALKANE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-0713846-B1 | PROCESS FOR PRODUCING CYCLOALKANOL AND CYCLOALKANONE | UBE INDUSTRIES (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5728890-A | DECOMPOSING CYCLOALKYLHYDROPEROXIDE BY CONTACT WITH A RUTHENIUM COMPLEX | UBE INDUSTRIES, LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0713846-A1 | PROCESS FOR PRODUCING CYCLOALKANOL AND CYCLOALKANONE | UBE INDUSTRIES, LTD. (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081848-A1 | METHOD FOR PRODUCING OXIDATION PRODUCT OF CYCLOALKANE | CBR3, CBR1, CYCS | CA1 3560/4885CA2 2302/4885CA12 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.